All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On Wednesday 21 March 2018, an oral abstract session was held at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). The fourth talk in this session was given by Chikako Ohwada from Chiba University, Department of Hematology, Chiba, Japan, and was entitled “A multicenter observational study of chronic and late acute graft-versus-host disease defined by 2005 NIH criteria: a prospective validation of Japanese cohort”. This article is based on data presented at the live session, which may supersede information in the pre-published ASH abstract.
Doctor Ohwada reported results of a prospective validation study of the 2005 NIH consensus GvHD criteria in Asian population. In total, 406 patients (median age at HCT = 50 years) were enrolled who underwent allo-HCT between May 2012 to June 2014 in 16 centers of the Kanto Study Group for Cell Therapy.
The speaker concluded that these findings provided a complete profile of late acute and chronic GvHD for the first time in a Japanese prospective cohort including organ involvement and treatment outcomes. “The incidence of late acute and chronic GVHD in our study was lower than that reported from prospective observation in a North-American cohort (Arora et al. Biol Blood Marrow Transplant, 2016). This discrepancy outlines different characteristics between the cohorts, probably reflecting both graft sources and genetic backgrounds.”
Subscribe to get the best content related to GvHD delivered to your inbox